UNSPSC 51191530: Aminometradine

This classification denotes a diuretic with the molecular formula C9H13N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PPM8SX5Q3V, chemically known as 6-amino-3-ethyl-1-(2-propenyl)-2,4(1h,3h-)-pyrimidinedione but generally known as aminometradine, which bears US NIH Compound Identifier 12551. European Medicines Agency schedules Aminometradine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05441MIG.

UNSPSC 51191530 Aminometradine is a Commodity code that in practice captures chemical supplies for municipal water treatment and pharmaceutical products distributed through state and local health and human services networks. State and local governments procure under this code primarily for two distinct operational categories: water pollution control chemicals such as sodium bisulfite for municipal treatment facilities, and generic multi-source pharmaceuticals and over-the-counter products for distribution across state and local government health care and institutional settings. Issuing bodies include municipal water utilities, state departments of administration overseeing cooperative purchasing alliances, and multistate purchasing consortia that aggregate demand across participating jurisdictions.

Recent activity centers on two geographically dispersed procurement streams. The City of Meriden, Connecticut, issued an IFB (B027-15) due July 29, 2026, for sodium bisulfite chemical supply to its Water Pollution Control Facility, with unit-cost-based pricing and performance and payment bonds required. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, released an RFP (S1070000015802) due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC across participating state and local government facilities, including Oregon; awards were to take effect July 1, 2026, with evaluation weighted 75 percent on price competitiveness and 25 percent split among fixed pricing, administrative compliance, EDI capability, and the 3 percent administrative fee. Vendors must maintain compliance with FDA requirements, cGMP, DSCSA, and carry comprehensive insurance including $5 million in commercial general liability and network security and privacy coverage.